News Releases

Select year
Categories

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

May 16, 2024 | Products

Read more

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

May 07, 2024 | Corporate | Financial

Read more

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

May 07, 2024 | Products | Corporate

Read more

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 30, 2024 | Corporate | Financial

Read more

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Apr 17, 2024 | Products

Read more

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Apr 16, 2024 | Products

Read more

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Apr 09, 2024 | Products

Read more

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Mar 21, 2024 | Products

Read more

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Mar 20, 2024 | Products

Read more

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Feb 27, 2024 | Financial | Corporate

Read more

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Feb 27, 2024 | Products

Read more

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 21, 2024 | Financial | Corporate

Read more

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Feb 15, 2024 | Corporate | Products

Read more

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Feb 01, 2024 | Corporate

Read more

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Jan 30, 2024 | Corporate

Read more

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

Jan 18, 2024 | Corporate | Products

Read more

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

Jan 09, 2024 | Products

Read more

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 03, 2024 | Corporate

Read more